June 11, 2014 by Arezu Sarvestani
DFine Inc. begins enrolling patients in a clinical trial of its STAR tumor ablation system, designed to “melt” tumors with radiofrequency energy.
Spinal therapies maker DFine Inc. launched enrollment in a clinical trial of its STAR tumor ablation system, evaluating the technology in treatment of spinal tumors.
The new EU-STAR clinical trial will enroll 40 patients at 5 centers in Germany and France, DFine reported. Researchers are looking to examine patients’ pain from 1 month following the procedure out to 6 months, as well as patients’ function, quality of life and reliance on pain medications.
